Retina Implant AG: Dr. Katarina Stingl wins Retinitis Pigmentosa Research Prize 2017
(Reutlingen/Berlin) – This year´s Retinitis Pigmentosa Research Prize for preventing blindness, which is jointly awarded by the PRO RETINA Deutschland patient associations and Retina Suisse, was given to Dr. Katarina Stingl. The consultant ophthalmologist received the award during the 115th Congress of the German Society of Ophthalmology (DOG) in Berlin in recognition of two studies relating to sub-retinal electronic implants in patients with retinitis pigmentosa.
Prof. Eberhart Zrenner, Chairman of the Scientific and Medical Advisory Board of PRO RETINA Deutschland e.V., a self-help group by and for people with retinal degeneration, delivered the laudation and stressed that Dr. Stingl´s work makes her one of the most promising young scientists in the field of clinical experimental research into degenerative retinal conditions and their treatment. Dr. Stingl qualified as a university lecturer at Eberhard Karls University of Tübingen, in 2015, and has been working as a consultant for congenital retinal conditions in the ophthalmology department there since 2016.
“ Retina Implant AG feels that the scientific work of Dr. Stingl is of vital importance. We would like to congratulate her on this award, and thank her for her valuable scientific contribution,“ explains Reinhard Rubow, CEO of Retina Implant AG. „The Retinitis Pigmentosa Research Prize 2017 also motivates our employees to continue their intensive efforts in researching and treating rare congenital retinal conditions. PRO RETINA´s impetus and initiatives help shape the interaction between hospitals, patients and doctors – and that includes this prize. The PRO RETINA patient register was also launched at the DOG. This is hugely important for clinical research, and we hope that as many patients as possible will join the register so that future research such as that of Dr. Stingl will be of increasing benefit for all RP patients.“
Contact form for the PRO RETINA Deutschland e.V. patient register:
http://www.pro-retina.de/forschungsfoerderung/patientenregister/formular
About Retina Implant AG
Retina Implant AG researches and develops innovative treatments and high-tech products for people suffering from retinitis pigmentosa (RP). The subretinal RETINA IMPLANT Alpha AMS can help blind patients regain a certain degree of useful sight. The CE-approved microchip is implanted beneath the retina (subretinally) at specialist RI implantation centres.
Transcorneal electrical stimulation (TES treatment) with the RI OkuStim® system offers RP patients with sufficient residual vision the opportunity to slow down the progression of the disease.
The company, based in Reutlingen, employs around 45 people and is managed by Reinhard Rubow (CEO and speaker of the Management Board), Jürgen Klein (Member of the Board, Sales & Marketing) and Dr. Alfred Stett (CTO, Member of the Board).
Company-Contact
Retina Implant AG
Ines Wülker
Gerhard-Kindler-Str. 13
72770 Reutlingen
Phone: + 49 71 21 3 64 03 – 289
E-Mail: ines.wuelker@retina-implant.de
Url: http://implant.de
Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de
